Founded in 2010, with TRG’s investment in 2019, Amethyst today operates one of the largest independent networks of cancer treatment centres in Europe, with 19 centres across France, Poland, Romania, the UK, Italy, and Austria. Amethyst delivers a comprehensive range of oncology services, primarily radiotherapy, and treats over 50,000 patients annually.
Amethyst has built a strong reputation among both the medical community (including circa one hundred doctors working in its centres) and its patients, supported by a team of over 500 highly skilled professionals. Its modern, well-invested infrastructure includes around 40 linear accelerators, the core technology used to deliver innovative radiotherapy treatments, positioning Amethyst as one of the largest radiotherapy providers in Europe.
Colin Clark, Partner & Head of Europe at The Rohatyn Group, commented: “It has been our pleasure to partner with the founding shareholders and management of Amethyst, as we worked together to deliver strong growth and scale the business across key European markets. Under TRG’s ownership, the company delivered a combination of organic and inorganic growth in existing markets, as well as successfully entering new markets through add-on acquisitions. We are confident the company is well positioned to continue its strong trajectory and has a bright future ahead.”
About TRG
Founded in 2002, The Rohatyn Group is an asset management firm focused on emerging markets and real assets. Headquartered in New York the firm is comprised of ~140 professionals based in 16 countries across North and South America, Europe, the Middle East, Africa, India, Southeast Asia, and Oceania. Specializing in late-stage growth and capital buyouts, TRG’s regionally focused Private Equity teams generally pursue mid-market opportunities across various sectors in Emerging Europe, Latin America, India and Africa. For more information, please visit www.rohatyngroup.com